Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
City A.M. | London's Business Newspaper - News, Opinion, & Anal…
May 7, 2026
Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026
Discussion in the ATmosphere